Immune Design Corp. said the FDA blessed its plans to initiate a pivotal phase III of CMB-305, its prime-boost vaccine approach against NY-ESO-1-expressing tumors, in individuals with locally advanced unresectable or metastatic synovial sarcoma, a subtype of soft tissue sarcoma.